InnoCan Pharma Corporation (INNO)
CSE
Closed
Aug 24, 2026
Day's Range
2.2452 wk Range
2.00Overview - INNO - InnoCan Pharma Corporation
Key Statistics
Valuation
Enterprise Value
10.51M
P/E (Trailing)
‪-9.00‬
PEG Ratio
‪-0.13‬
Price / Sales (TTM)
‪0.40‬
Price / Book
‪1.40‬
EV / EBITDA
‪-3.06‬
Profitability
Gross Margin
‪91.10%‬
Profit Margin
‪-5.98%‬
Operating Margin
‪-12.15%‬
Return on Assets
‪-14.59%‬
Return on Equity
‪-13.47%‬
Ownership
Shares Outstanding
4.49M
Float
3.58M
Held by Insiders
‪20.31%‬
Held by Institutions
‪0.00%‬
Price stats
Beta
‪-0.21‬
50-Day Avg
‪2.86‬
200-Day Avg
‪6.23‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - INNO - InnoCan Pharma Corporation
Peers - INNO - InnoCan Pharma Corporation
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on CSE.
Profile Summary - INNO - InnoCan Pharma Corporation
About
InnoCan Pharma Corporation is a pharmaceutical technology company founded in 2018 and headquartered in Calgary, Canada. It specializes in innovative drug delivery platforms that combine cannabidiol (CBD) with other pharmaceutical ingredients to treat chronic pain, epilepsy, and other medical conditions. Its…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
